EP1843772A1 - Formulations intraveineuses d'inhibiteurs de la pde-5 - Google Patents

Formulations intraveineuses d'inhibiteurs de la pde-5

Info

Publication number
EP1843772A1
EP1843772A1 EP06706165A EP06706165A EP1843772A1 EP 1843772 A1 EP1843772 A1 EP 1843772A1 EP 06706165 A EP06706165 A EP 06706165A EP 06706165 A EP06706165 A EP 06706165A EP 1843772 A1 EP1843772 A1 EP 1843772A1
Authority
EP
European Patent Office
Prior art keywords
vardenafil
pde
acid
intravenous
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06706165A
Other languages
German (de)
English (en)
Inventor
Peter Serno
Helmut Haning
Frank Reetz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Healthcare AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare AG filed Critical Bayer Healthcare AG
Publication of EP1843772A1 publication Critical patent/EP1843772A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • the invention relates to novel applications of intravenous administration forms of PDE inhibitors and novel pharmaceutical formulations for this purpose.
  • PDE in particular the PDE 5 inhibitors are known as potent pharmaceutical active ingredients and are used for the treatment of diseases.
  • the compound vardenafil is systematically named ⁇ 2-ethoxy-5- [4-ethyl-1-piperazinyl) sulfonyl] -phenyl ⁇ -5-methyl-7-propyl-hmidazo [5, l - /] -triazine-4 (3H) -one and their physiologically acceptable salts, for example in WO99 / 24433.
  • Other PDE 5 inhibitors are
  • DA8159 Enantiomers of 5- [2-propyloxy-5- (1-methyl-2-pyrrolidinylethylamidosulfonyl) phenyl] -1-methyl-3-propyl-1,6-dihydro-7 ⁇ -pyrazolo (4,3-d) pyrimidines -7-one as described in WO 2001098304,
  • TA-1790 avanafil, (S) -2- (2-hydroxymethyl-1-pyrrolidinyl) -4- (3-chloro-4-methoxybenzylamino) - 5 - [(2-pyrrolidinylmethyl) carbamoyl] pyrimidines
  • EMD-221829 4- ⁇ 4 - [(3-chloro-4-methoxybenzyl) amino] [l] benzothieno [2,3-d] pyrimidin-2-yl ⁇ -cyclohexanecarboxylic acid ethanolamine salt,
  • ABT724 2 - [(4-pyridin-2-yl-piperazin-1-yl) methyl] -1 H-benzimidazole.
  • Vardenafil like sildenafil and tadalafil, inhibits intracellular degradation of cGMP by PDE 5 inhibition.
  • increased intracellular cGMP levels result after NO activation.
  • the mechanism has been used to treat erectile dysfunction and to treat and prevent other diseases such as hypertension, neuronal hypertension, stable and unstable angina, peripheral and cardiovascular diseases, arrhythmias, for the treatment of thromboembolic disorders and ischaemias such as myocardial infarction, stroke, transient ischemic attacks , Angina pectoris, peripheral circulatory disorders, for the prevention of restenosis after thrombolytic therapy, percutaneous transluminal angioplasty (PTA), percutaneous transluminal coronary angioplasty (PTCA) and bypass.
  • PTA percutaneous transluminal angioplasty
  • PTCA percutaneous transluminal coronary angioplasty
  • the differentiated expression of the phosphodiesterases in different cells, tissues and organs, as well as the differentiated subcellular localization of these enzymes, allow for selective addressing of the various cGMP-regulated processes, in particular in the case of intravenous administration of the PDE inhibitors. Therefore, the preparations according to the invention are suitable for the prophylaxis and / or treatment of diseases in which an increase in cGMP concentration is beneficial, i. Diseases related to; cGMP-regu-. lated processes (usually simply referred to as 'cGMP-related diseases' in English).
  • the PDE 5 inhibitors also enhance the action of substances such as EDRF (endothelium-derived relaxing factor), ANP (atrial natriuretic peptide), nitro-vasodilators and all other substances that in a different way than phosphodiesterase inhibitors cGMP Increase concentration.
  • EDRF endothelium-derived relaxing factor
  • ANP atrial natriuretic peptide
  • nitro-vasodilators all other substances that in a different way than phosphodiesterase inhibitors cGMP Increase concentration.
  • PDE 5 inhibitors now also allow treatment of cardiovascular diseases after administration in the form of the infusion formulations according to the invention.
  • cardiovascular diseases include: hypertension, heart failure, pulmonary hypertension, nitrate-induced tolerance, neuronal hypertension, stable and unstable angina, peripheral and cardiac vascular disease, achieving or improving preconditioning effect, cardiac ischemia, acute myocardial infarction, reperfusion injury, especially after myocardial infarction , Arrhythmias, thromboembolic disorders and ischaemias such as myocardial infarction, coronary heart disease, stroke, transitory. and ischemic attacks, angina pectoris, peripheral circulatory disorders, Raynaud's syndrome and intermittent claudication. They are also useful in the prevention of restenosis following thrombolytic therapy, percutaneous transluminal angioplasty (PTA), percutaneous transluminal coronary angioplasty (PTCA) and bypass
  • the infusion formulations of PEDE 5 inhibitors according to the invention can be used for the treatment of diseases of the urogenital system such as prostatic hypertrophy, incontinence, bladder diseases, erectile dysfunction, priapism, Peyronie's disease, preterm labor, premature ejaculation, male infertility, insufficient sperm motility, dysmenorrhea, polycystic ovary Syndromes, incontinence (eg urge incontinence), acute and chronic renal failure, renal syndrome, glomerular disease, nephritis, tubulo-intestinal disorders, glomuleropathy, female infertility, female sexual dysfunction and female sexual arousal disorder in the fort Planting medicine is possible, for example to promote growth and survival of oocytes, zygotes, embryos or fetuses, to increase weight in premature birth, to increase milk production in mammals, especially in humans, in premature labor and pre-eclampsia.
  • diseases of the urogenital system
  • Another area of application is the treatment and / or prophylaxis of disorders of perception, concentration performance, learning performance and / or memory performance, especially if the disorder is a consequence of dementia.
  • the formulations used according to the invention are particularly suitable for improving perception, concentration performance, learning performance, or memory performance for cognitive disorders, such as those found particularly in situations / diseases / syndromes such as mild cognitive impairment, age-associated learning and memory disorders, age-associated memory loss, vascular dementia, craniocerebral trauma, stroke, dementia that occurs after strokes ("post stroke dementia”), and post-traumatic brain injury trauma.
  • Alzheimer's disease vascular dementia
  • dementia with Lewy bodies dementia with degeneration of the froirt lobes including Pick's Syndrome, Parkinson's disease, progressive nuclear palsy, dementia with cortic and jasal degeneration, amyolateral sclerosis (ALS), Huntington's disease, multiple sclerosis, thalamic degeneration, Creutzfeld-Jacob dementia, HTV dementia, schizophrenia with dementia or Korsakoff's psychosis, treatment of depression, amnesia, anxiety disorders, autism, speech disorders, Lennox syndrome and epilepsy.
  • ALS amyolateral sclerosis
  • HTV dementia thalamic degeneration
  • schizophrenia with dementia or Korsakoff's psychosis treatment of depression, amnesia, anxiety disorders, autism, speech disorders, Lennox syndrome and epilepsy.
  • inventive intravenous formulations of PDFE 5 inhibitors is possible for the treatment or prophylaxis of ocular disorders such as glaucoma, especially acute glaucoma, central retinal or posterior ciliary artery occlusion, central retinal venous occlusion, optic neuropathy such as anterior ischemic optic neuropathy and glaucomatous optic neuropathy, as well as macular degeneration.
  • ocular disorders such as glaucoma, especially acute glaucoma, central retinal or posterior ciliary artery occlusion, central retinal venous occlusion, optic neuropathy such as anterior ischemic optic neuropathy and glaucomatous optic neuropathy, as well as macular degeneration.
  • diabetes insulin resistance
  • hyperglycemia diabetic gastroparesis
  • diabetic nephropathy diabetic neuropathy
  • diabetic retinopathy diabetic gangrene
  • diabetic glomerulosclerosis diabetic dermatopathy, diabetic arthropathy, diabetic dermatopathy and diabetic cataract.
  • inventive intravenous formulations of PDE 5 inhibitors are also suitable for the treatment of the following disorders: disorders of peristalsis of the stomach and esophagus, liver diseases such as cirrhosis, portal hypertension, pancreatitis, inflammatory bowel disease (eg, Crohn's disease and ulcerative colitis ) Disorders of gastric motility, further supporting and promoting liver regeneration after chimgous liver resection or liver cancer, and inhibiting oesophageal muscle contraction (eg, nutcracker esophagus, spastic esophageal disease).
  • disorders of peristalsis of the stomach and esophagus liver diseases such as cirrhosis, portal hypertension, pancreatitis, inflammatory bowel disease (eg, Crohn's disease and ulcerative colitis )
  • inflammatory bowel disease eg, Crohn's disease and ulcerative colitis
  • oesophageal muscle contraction eg, nutcracker esophagus, spa
  • inventive formulations can be used for the prophylaxis and / or treatment of: osteoporosis, psoriasis, cancer, cystic fibrosis, alopecia, pain, tinnitus, hearing loss, COPD, asthma, bronchitis and allergic rhinitis, fibrotic diseases, arteriosclerosis, leukemia (eg chronic lymphocytic leukemia), platelet adhesion and aggregation in renal ischemia, achalasia, hypertensive LES 5 lupus, scleroderma, hair loss or alopecia, multiple sclerosis and rheumatoid arthritis, allergy, osteoporosis, autoimmune diseases, cachexia, hyperlipidemia and dyslipidemia and migraine.
  • leukemia eg chronic lymphocytic leukemia
  • LES 5 lupus eg chronic lymphocytic leukemia
  • scleroderma eg chronic lymphocytic leukemia
  • Another aspect of the invention are intravenously administrable formulations of PDE 5 inhibitors, in particular vardenafil.
  • vardenafil Solutions of vardenafil and its physiologically acceptable salts are described in WO99 / 2433.
  • the therapeutically active compound should be present in a concentration of 0.5 to 90 wt .-% of the total mixture.
  • concentration of the active ingredient in the formulation only allows rapid intravenous delivery of the drug, for example as a bolus injection or infusion at a very low rate of infusion.
  • an easily handled and well tolerated intravenous formulation of PDE 5 inhibitors such as vardenafil can be obtained when 0.0004 to 0.1% (w / v) of the PDE inhibitor is free base or a salt be dissolved in an aqueous solvent.
  • solutions which contain an acid in addition to the PDE inhibitor In this case, a molar ratio of 1: 0.9 to 1: 2.0 (PDE inhibitor: acid) is particularly preferred.
  • PDE inhibitors in the form of a salt the amount of acid to be added is reduced by the amount that has already been used for salt formation. In the case of polybasic acids, depending on the acid strength of the particular dissociation stage, the stated amount of acid may optionally be divided by the number of protons released per molecule of acid.
  • the infusion solutions according to the invention have the advantage of being well tolerated after parenteral administration Application, a virtually immediate establishment of effective plasma concentrations, good controllability of drug delivery, since the infusion rate can be reduced if undesirable side effects occur.
  • a particular advantage is the very high bioavailability after administration of the preparations according to the invention, which is surprisingly 6 to 7 times greater than that of an orally administered tablet.
  • the PDE 5 inhibitor in amorphous, crystalline or solvent-containing form is dissolved in an aqueous solvent to prepare the solutions according to the invention.
  • one or more acids are added to this.
  • Suitable acids are, for example, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, citric acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, fumaric acid, glucgheptonic acid, gluconic acid, glucuronic acid, glutamic acid, hydrochloric acid, lactic acid, lactobionic acid, maleic acid, malic acid, malonic acid , Methanesulfonic acid, naphthalenesulfonic acid, naphthalene-disulfonic acid, nitric acid, phosphoric acid, succinic acid, sulfuric acid, tartaric acid, toluenesulfonic acid, mono-
  • an isotonizing agent may be added to formulations according to the invention, for example sodium chloride, glucose, fructose, mannitol, sorbitol, glycerol, acetate, citrate, phosphate or lactate buffers or amino acids.
  • the pH of the preparations can be adjusted with one of the acids mentioned or at already too acidic pH with a base such as sodium hydroxide, trometamol, arginine or lysine.
  • a pH range of 3 to 7 is preferred for the formulations according to the invention.
  • parenterally administrable organic solvents such as ethanol, propylene glycol or polyethylene glycol, surfactants or polymers such as polyvinylpyrrolidone, polysorbate, poloxamer, Cremophor, Solutol HS 15, phospholipids and native or substituted cyclodextrins.
  • the formulations according to the invention are filled into known containers for parenteral administration, for example in injection vials or glass infusion bottles with stoppers, in flexibags or in other large or small-volume containers made of plastic, in prefilled syringes or carpules.
  • the filling is also possible in the blow-fill-seal process in plastic containers.
  • Vardenafil or a vardenafil salt for example, are dissolved in the solvent (usually water) together with acid, isotonizing agents and optionally further auxiliaries to produce the preparations according to the invention. After adjusting the pH is made up with water to the total amount used, sterile filtered through 0.2 micron filter membranes and bottled.
  • a sterilization of the filled solution is preferably in the final container, for example for 15 minutes at 121 0 C.
  • the use of packaging materials that survive this temperature is not harmless, is However, aseptic preparation without or with subsequent heat treatment, possibly at lower temperatures than 121 0 C possible.
  • Concentrates represent a particular embodiment of the invention.
  • a concentrated solution of vardenafil is first prepared and marketed.
  • the preparation of the inventive infusion solution is then carried out by the user, for example by adding the concentrate solution to a standard infusion or by continuous dilution of the concentrate via a Y-piece.
  • the infusion solutions according to the invention can be administered intravenously in different ways, depending on the drug dose, the drug concentration and the field of application.
  • the administration as bolus injection, the application in the form of a gravity drip infusion or pumping through an infusion tube pump or infusion syringe pump are possible.
  • the infusions are administered to peripheral veins, but in patients undergoing intensive care, central venous or, in special cases, arterial administration is also possible.
  • Example 1 (comparison):
  • Non-inventive preparation drug concentration 0.005 mg / ml
  • the solution contains to a considerable extent undissolved active substance components and is not suitable for intravenous infusion.
  • Vardenafil dihydrate 0.50 g
  • the solution is unstable. When the solution is prepared, 6.5% of vardenafil N-oxide forms. Its content increases to 11% after heat sterilization of the solution.
  • Vardenafil dihydrate (equivalent to 2.00 mg vardenafil) 2.15 mg
  • Example 6 107.4 mg of vardenafil dihydrate, 27.7 mg of tartaric acid and 9 g of sodium chloride are dissolved in one liter of water for injection purposes. The solution is sterile filtered, filled to 2 ml in pre-filled syringes and sterilized. Each pre-filled syringe contains 0.2 mg vardenafil.
  • Example 6 107.4 mg of vardenafil dihydrate, 27.7 mg of tartaric acid and 9 g of sodium chloride are dissolved in one liter of water for injection purposes. The solution is sterile filtered, filled to 2 ml in pre-filled syringes and sterilized. Each pre-filled syringe contains 0.2 mg vardenafil.
  • Example 6 Example 6
  • vardenafil dimesilate monohydrate is filled in 1000 ml physiological saline.
  • the solution is sterile filtered and filled under aseptic conditions to 250 ml in infusion bottles.
  • Each infusion bottle contains 1 mg vardenafil.
  • tadalafil 0.005 kg of tadalafil is dissolved in 30 kg of polyethylene glycol 400 and 30 kg of ethanol 96%. It is made up to 200 liters with water for injections. The solution is sterile filtered and aseptically filled into infusion bottles to 100 ml.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne un nouvelle forme pharmaceutique d'inhibiteurs de PDE pour administration intraveineuse et son utilisation dans le traitement de maladies.
EP06706165A 2005-01-15 2006-01-05 Formulations intraveineuses d'inhibiteurs de la pde-5 Withdrawn EP1843772A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005001989A DE102005001989A1 (de) 2005-01-15 2005-01-15 Intravenöse Formulierungen von PDE-Inhibitoren
PCT/EP2006/000045 WO2006074872A1 (fr) 2005-01-15 2006-01-05 Formulations intraveineuses d'inhibiteurs de la pde-5

Publications (1)

Publication Number Publication Date
EP1843772A1 true EP1843772A1 (fr) 2007-10-17

Family

ID=36250941

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06706165A Withdrawn EP1843772A1 (fr) 2005-01-15 2006-01-05 Formulations intraveineuses d'inhibiteurs de la pde-5

Country Status (17)

Country Link
US (1) US20080280914A1 (fr)
EP (1) EP1843772A1 (fr)
JP (1) JP2008526907A (fr)
KR (1) KR20070098911A (fr)
CN (1) CN101102774A (fr)
AU (1) AU2006205908A1 (fr)
BR (1) BRPI0606322A2 (fr)
CA (1) CA2594709A1 (fr)
DE (1) DE102005001989A1 (fr)
IL (1) IL184569A0 (fr)
MA (1) MA29169B1 (fr)
MX (1) MX2007008442A (fr)
NO (1) NO20074109L (fr)
RU (1) RU2007130997A (fr)
SG (1) SG158863A1 (fr)
WO (1) WO2006074872A1 (fr)
ZA (1) ZA200705736B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100914445B1 (ko) * 2005-06-10 2009-08-28 동아제약주식회사 피라졸로피리미디논 유도체를 유효성분으로 함유하는 간질환의 예방 및 치료제
DE102007004144A1 (de) 2007-01-22 2008-07-24 Androtec Gmbh Lichtstrahlempfänger mit Störsignalunterdrückung
WO2008151734A1 (fr) * 2007-06-13 2008-12-18 Bayer Schering Pharma Aktiengesellschaft Inhibiteurs de la phosphodiestérase (pde) destinés au traitement des troubles de l'audition
JP2011184433A (ja) * 2010-02-09 2011-09-22 Daiichi Sankyo Healthcare Co Ltd バルデナフィル含有内服液剤組成物
WO2011162320A1 (fr) * 2010-06-23 2011-12-29 国立大学法人九州大学 Combinaison d'egcg ou egcg méthylé et un inhibiteur de pde
TWI562991B (en) * 2012-04-23 2016-12-21 Otsuka Pharma Co Ltd Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
JP6120985B2 (ja) * 2012-12-04 2017-04-26 アリビオ， インコーポレーテッド ホスホジエステラーゼタイプ５活性阻害剤を含む神経細胞のアポトーシス抑制用組成物
CN103479570A (zh) * 2013-09-27 2014-01-01 南京奇鹤医药科技有限公司 一种伐地那非注射液的制备方法
US11980618B2 (en) * 2018-08-06 2024-05-14 Nicox S.A. Nitric oxide releasing phosphodiesterase type 5 inhibitor
US20220362253A1 (en) 2018-12-06 2022-11-17 Glaxosmithkline Intellectual Property Development Limited Novel pharmaceutical formulation
CN112773898A (zh) * 2019-11-11 2021-05-11 广州华真医药科技有限公司 磷酸二酯酶5抑制剂在制备抗纤维化疾病药物中的应用
JP7399284B2 (ja) * 2019-11-14 2023-12-15 スンチョンヒャン ユニバーシティ インダストリー アカデミー コーポレーション ファウンデーション 脳卒中または脳卒中による後遺症治療のためのシルデナフィル及びｒｏｃｋ阻害剤の用途
JP2023516891A (ja) * 2020-02-05 2023-04-21 ニコックス エス．エー． 緑内障及び高眼圧症の処置のための組成物
TW202233623A (zh) * 2020-11-09 2022-09-01 南韓商日東製藥股份有限公司 氮氧化物供與的pde-5及/或pde-6抑制劑化合物及其用途
CN115969781A (zh) * 2023-01-09 2023-04-18 北京悦康科创医药科技股份有限公司 一种枸橼酸爱地那非注射剂及其制备方法和用途

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2036070A (en) * 1932-03-18 1936-03-31 Westinghouse X Ray Co Inc X-ray exposure timer
US2705715A (en) * 1952-10-29 1955-04-05 American Cyanamid Co Purine compounds and methods of preparing the same
GB1042471A (en) * 1963-01-16 1966-09-14 Ilford Ltd Penta-azaindenes, their production and use in photographic emulsions
GB1051734A (fr) * 1963-01-16
US3169129A (en) * 1963-05-10 1965-02-09 American Cyanamid Co 2-ortho-hydroxy-phenyl-4-(3h)-quinazolinones
USRE26565E (en) * 1966-03-02 1969-04-29 Table iii
GB1493685A (en) * 1970-12-15 1977-11-30 May & Baker Ltd 8-azapurinones
BE791025A (fr) * 1971-11-19 1973-05-07 Allen & Hanburys Ltd Composes heterocycliques
GB1457873A (en) * 1973-01-04 1976-12-08 Allen & Hanburys Ltd Imidazotriazines
US4060615A (en) * 1976-02-18 1977-11-29 Mead Johnson & Company 2-Piperazinyl-6,7-dimethoxyquinazolines
GB1561345A (en) * 1976-10-22 1980-02-20 May & Baker Ltd 8 - azapuring - 6 - ones
US4159330A (en) * 1976-11-02 1979-06-26 Carlo Erba S.P.A. 2-Disubstituted phenyl-3,4-dihydro-4-oxo-quinazoline derivatives and process for their preparation
DK109578A (da) * 1977-03-25 1978-09-26 Allen & Hanburys Ltd Fremgangsmaade til fremstilling af heterocycliske forbindelser
EP0054132B1 (fr) * 1980-12-12 1984-10-10 Dr. Karl Thomae GmbH Pyrimidones, leur préparation et médicaments les contenant
US4431440A (en) * 1981-02-20 1984-02-14 American Cyanamid Company Method to alter or control the development and/or the life cycle of various plant species
US4666908A (en) * 1985-04-05 1987-05-19 Warner-Lambert Company 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use
CA1303037C (fr) * 1987-02-02 1992-06-09 Smith Kline & French Laboratories Limited Derives de purinone utilises comme bronchodilatateurs,vasodilatateurs et agents anti-allergiques
US5254571A (en) * 1988-04-21 1993-10-19 Smith Kline & French Laboratories Ltd. Chemical compounds
DE68908786T2 (de) * 1988-06-16 1994-03-17 Smith Kline French Lab Condensierte Pyrimidinderivate, Verfahren und Zwischenprodukte zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen.
US5075310A (en) * 1988-07-01 1991-12-24 Smith Kline & French Laboratories, Ltd. Pyrimidone derivatives as bronchodilators
US4923874A (en) * 1988-07-21 1990-05-08 G. D. Searle & Co. Use of 8-azapurin-6-one derivatives for control of hypertension
GB8817651D0 (en) * 1988-07-25 1988-09-01 Smith Kline French Lab Chemical compounds
GB8827988D0 (en) * 1988-11-30 1989-01-05 Smith Kline French Lab Chemical compounds
US5574020A (en) * 1989-09-28 1996-11-12 Eli Lilly And Company Tilmicosin formulation
WO1991015194A1 (fr) * 1990-04-11 1991-10-17 The Upjohn Company Masquage du gout de l'ibuprofene par enrobage en lit fluidise
US5250534A (en) * 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
GB9114760D0 (en) * 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
US5316906A (en) * 1991-08-23 1994-05-31 Molecular Probes, Inc. Enzymatic analysis using substrates that yield fluorescent precipitates
GB9126260D0 (en) * 1991-12-11 1992-02-12 Pfizer Ltd Therapeutic agents
US5294612A (en) * 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
US5734053A (en) * 1992-06-26 1998-03-31 Pfizer Inc Purinone antianginal agents
GB9218322D0 (en) * 1992-08-28 1992-10-14 Pfizer Ltd Therapeutic agents
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
US5556847A (en) * 1994-10-27 1996-09-17 Duquesne University Of The Holy Ghost Methods of effecting memory enhancement mediated by steroid sulfatase inhibitors
GB9423911D0 (en) * 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
US6548490B1 (en) * 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
ID25871A (id) * 1997-11-12 2000-11-09 Bayer Ag Imidazotriazinon tersubstitusi-2-fenil
US6221402B1 (en) * 1997-11-20 2001-04-24 Pfizer Inc. Rapidly releasing and taste-masking pharmaceutical dosage form
GT199900061A (es) * 1998-05-15 2000-10-14 Pfizer Formulaciones farmaceuticas.
DE19827640A1 (de) * 1998-06-20 1999-12-23 Bayer Ag 7-Alkyl- und Cycloalkyl-substituierte Imidazotriazinone
UA67802C2 (uk) * 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
IL130968A (en) * 1999-07-15 2002-12-01 Shmuel Simon Pharmaceutical composition comprising sildenafil or its analogs, useful for the treatment of tinnitus and hearing loss
IL137429A0 (en) * 1999-07-28 2001-07-24 Pfizer Prod Inc Methods and compsitions for treating diseases and conditions of the eye
US6075028A (en) * 1999-09-23 2000-06-13 Graham; Richard Method of treating Tourette's syndrome and related CNS disorders
US6503908B1 (en) * 1999-10-11 2003-01-07 Pfizer Inc Pharmaceutically active compounds
TWI224966B (en) * 1999-11-02 2004-12-11 Pfizer Pharmaceutical composition (I) useful for treating or preventing pulmonary hypertension in a patient
JP2003519150A (ja) * 1999-12-24 2003-06-17 バイエル アクチェンゲゼルシャフト 新規なイミダゾ［１，３，５］トリアジノン類及びその使用
GB0000561D0 (en) * 2000-01-11 2000-03-01 Pfizer Ltd Treatment of diabetic ulcers
GB0008694D0 (en) * 2000-04-07 2000-05-31 Novartis Ag Organic compounds
AU2001257146B2 (en) * 2000-04-19 2006-11-30 Johns Hopkins University Methods for prevention and treatment of gastrointestinal disorders
DE60103299T2 (de) * 2000-10-30 2005-05-12 Lupin Ltd., Mumbai Schnell zerfallende cefuroxim axetil enthaltende arzneizusammensetzung mit verzögerter wirkstoffabgabe
CN100372536C (zh) * 2001-02-15 2008-03-05 田边三菱制药株式会社 在口腔中迅速崩解的片剂
DE10118306A1 (de) * 2001-04-12 2002-10-17 Bayer Ag Imidazotriazinonhaltige Zusammensetzungen zur nasalen Applikation
JP4540295B2 (ja) * 2001-05-09 2010-09-08 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト ２−フェニル置換イミダゾトリアジノンの新しい用途
GB0202254D0 (en) * 2002-01-31 2002-03-20 Pfizer Ltd Prevention of scarring
US7939102B2 (en) * 2002-06-07 2011-05-10 Torrent Pharmaceuticals Ltd. Controlled release formulation of lamotrigine
DE10232113A1 (de) * 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
DE10325813B4 (de) * 2003-06-06 2007-12-20 Universitätsklinikum Freiburg Prophylaxe und/oder Therapie bei der portalen Hypertonie
DE102004023069A1 (de) * 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2006074872A1 *

Also Published As

Publication number Publication date
BRPI0606322A2 (pt) 2009-06-16
MX2007008442A (es) 2007-09-06
CN101102774A (zh) 2008-01-09
IL184569A0 (en) 2007-10-31
NO20074109L (no) 2007-08-08
AU2006205908A1 (en) 2006-07-20
RU2007130997A (ru) 2009-02-20
MA29169B1 (fr) 2008-01-02
WO2006074872A1 (fr) 2006-07-20
CA2594709A1 (fr) 2006-07-20
ZA200705736B (en) 2008-12-31
DE102005001989A1 (de) 2006-07-20
JP2008526907A (ja) 2008-07-24
SG158863A1 (en) 2010-02-26
US20080280914A1 (en) 2008-11-13
KR20070098911A (ko) 2007-10-05

Similar Documents

Publication Publication Date Title
EP1843772A1 (fr) Formulations intraveineuses d'inhibiteurs de la pde-5
EP1778238B1 (fr) Solutions de perfusion de dihydropteridinones stables au stockage
DE602005001833T2 (de) Zusammensetzungen enthaltend Ecteinascidin und einen Disaccharide
DE102004023069A1 (de) Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
DE3320582A1 (de) Gliquidonhaltige zubereitungsformen und verfahren zu ihrer herstellung
DE60025627T2 (de) Pharmazeutische lösung von levosimendan
DE102004046235A1 (de) Arzneimittelzubereitung
EP2854765B1 (fr) Solution pharmaceutique de pemetrexed
NO175406B (no) Fremgangsmåte ved fremstilling av piroxam i vandig opplösning
EP0660711A1 (fr) Nouvelle utilisation d'inhibiteurs de la phosphodiesterase iv
AT397462B (de) Wässerige piroxicamlösungen
DE3722043A1 (de) Loesungen von oxazaphosphorinen mit verbesserter stabilitaet und verfahren zu deren herstellung
EP1216039B1 (fr) Nouvelle combinaison pour le traitement d'un dysfonctionnement sexuel
WO2003101456A1 (fr) Utilisation de composes stimulant le gmp cyclique
EP1638532A1 (fr) Forme galenique injectable de flupirtine
DE10048510A1 (de) Lagerstabile Infusionslösung des Ciprofloxacins mit verringertem Säuregehalt
CN1857281B (zh) 阿德福韦酯脂质体注射剂及其制备方法
DE102004046236A1 (de) Arzneimittelzubereitung
WO2004004736A1 (fr) Nouvelle utilisation d'imidazotriazinones
EP1458389B1 (fr) Solutions aqueuses du moxaverine destinees au traitement du dysfonctionnement erectile
AT512084A1 (de) Diazabicyclo- und diazaspiro-alkanderivate als phosphodiesterase-5 inhibitoren
AT390881B (de) Verfahren zur herstellung von pharmazeutischen loesungen von oxazaphosphorinen mit verbesserter stabilitaet
EP4046626A1 (fr) Utilisation d'une solution concentrée de pemetrexed
WO2001078731A1 (fr) Solutions de perfusion de ciprofloxacine a capacite de stockage amelioree

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070816

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: HR

RAX Requested extension states of the european patent have changed

Extension state: HR

Payment date: 20070816

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BAYER SCHERING PHARMA AG

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BAYER PHARMA AKTIENGESELLSCHAFT

17Q First examination report despatched

Effective date: 20120314

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120725